Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.50 |
| ▸ | CA2 | P00918 | 8/20 | 0.50 |
| ▸ | CA9 | Q16790 | 8/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29210282 | 0.90 | ALDH1A1 (0.45) | CA1CA2CA9CA12CA14 | |
| SCHEMBL8023017 | 0.89 | NPC1 (0.46) | CA1CA2CA9CA12CA14 | |
| SCHEMBL30687380 | 0.89 | NPC1 (0.46) | CA1CA2CA9CA12CA14 | |
| SCHEMBL28829377 | 0.86 | CA2 (0.49) | CA1CA2CA9CA12CA14 | |
| SCHEMBL30764868 | 0.85 | PTGS1 (0.47) | CA1CA2CA9CA12CA14 | |
| SCHEMBL11882155 | 0.85 | AKT1 (0.44) | CA1CA2CA9CA12CA14 | |
| SCHEMBL8012548 | 0.85 | CA1 (0.51) | CA1CA2CA9CA12CA14 | |
| SCHEMBL29169943 | 0.84 | CA12 (0.50) | CA1CA2CA9CA12CA14 | |
| Ammonia Solution, Strong SCHEMBL28389132 | 0.84 | CA1 (0.36) | CA1CA2CA9CA12CA14 | |
| SCHEMBL28745681 | 0.83 | ALDH1A1 (0.50) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5510387-A | ADMINISTERING A CRYSTALLINE GAMMA-MODIFICATION OF PARA-AMINOBENZENESULFANILAMIDE | Leonidov, Nikolai Borisovich (RU) | 1996-04-23 | — | — | US | claimed |
| EP-0630644-A1 | ANTI-MICROBIAL AND INTERFERON-INDUCING PHARMACEUTICAL COMPOUND | LEONIDOV, Nikolai Borisovich (RU) | 1994-12-28 | — | — | EP | claimed |
| US-9962398-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2018-05-08 | — | — | US | disclosed |
| EP-2590938-B1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC (CA) | 2017-06-07 | — | — | EP | disclosed |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC. (CA) | 2017-01-12 | — | — | US | disclosed |
| US-9463171-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2016-10-11 | — | — | US | disclosed |
| CN-103221388-B | For the novel sulfonamide compounds suppressing metastatic tumo(u)r to grow | 维理生物技术公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| CN-103221388-A | Novel sulfonamide compounds for inhibition of metastatic tumor growth | METASIGNAL THERAPEUTICS INC | 2013-07-24 | — | — | CN | disclosed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | disclosed |
| CN-101891967-B | Method for the reactive colouring of leather | BASF SE | 2013-02-27 | — | — | CN | disclosed |
| EP-0539530-B1 | PURIFICATION DIRECTED CLONING OF PEPTIDES | BIONEBRASKA INC (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5595887-A | GENE EXPRESSION, FORMING POLYPEPTIDES FOR PROTEIN PURIFICATION | BIONEBRASKA, INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5510387-A | ADMINISTERING A CRYSTALLINE GAMMA-MODIFICATION OF PARA-AMINOBENZENESULFANILAMIDE | Leonidov, Nikolai Borisovich (RU) | 1996-04-23 | — | — | US | disclosed |
| EP-0630644-A1 | ANTI-MICROBIAL AND INTERFERON-INDUCING PHARMACEUTICAL COMPOUND | LEONIDOV, Nikolai Borisovich (RU) | 1994-12-28 | — | — | EP | disclosed |
| EP-0539530-A4 | PURIFICATION DIRECTED CLONING OF PEPTIDES. | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0539530-A1 | PURIFICATION DIRECTED CLONING OF PEPTIDES | BIONEBRASKA, INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992001707-A1 | PURIFICATION DIRECTED CLONING OF PEPTIDES | BIONEBRASKA, INC. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1988009335-A1 | POLYMORPHS OF INOSINE AND METHODS OF MAKING AND USING THEM | GORDON PAUL (US) | 1988-12-01 | — | — | WO | disclosed |
| WO-1988008747-A1 | MICROENCAPSULATION | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA1 31/4885CA2 5/4885CA9 25/4885 |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA1 31/4885CA2 5/4885CA9 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.